Innate Pharma S.A. IPHYF
1.51 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
2.18 Day range 2.25
1.37 52-week range 2.25
- YTD
- -29.81%
- 1 year
- -24.55%
- Market cap
- 168.56M
- EPS (ttm)
- -0.59
- YTD return
- -29.81%
- 1-year return
- -24.55%
- Volume
- 200
- Avg volume
- 15
- Open
- 2.18
- Previous close
- 1.51
- Day's range
- 2.18 – 2.25
- 52-week range
- 1.37 – 2.25
- Earnings date
- Mar 21, 2024
2Y -0.73 (-32.59%)
Next earnings
Mar 21, 2024
Expected Mar 21, 2024. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Mar 23, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Mar 24, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
News
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference 
Innate Pharma (OTCMKTS:IPHYF) Stock Falls 32.9% – Here’s What Happened 
Innate Pharma Reports First Half 2026 Business Update and Financial Results 
Innate Pharma Announces Conference Call and Webcast 
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer 
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma 
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) 
Outcome of Innate Pharma's 2026 Annual General Meeting
Your note
Sign in to keep a note on IPHYF — it syncs with the Stock Master app.